CompAge 2020

Aims and scope

Ageing is a complex phenomenon that remains poorly understood and raises great challenges for science, medicine, and society. Age-related diseases, such as neurodegenerative diseases, remain largely uncured, with attrition rates in clinical trials reaching unprecedented levels. There is no consensus on prevention measures due to limited understanding of the complex interplay between the multiple manifestations of ageing across scales, systems and organs. The spectrum of possible trajectories of healthy and pathological ageing is extraordinarily entangled, multifactorial, and heterogeneous.

Describing, modelling, and predicting the progression of slowly evolving biological processes requires the development of specific computational and data-driven methods at the cross-roads of biostatistics, machine learning, mathematical modelling, knowledge modeling and numerical simulation.

CompAge 2020 aims to be a first-of-its-kind forum to communicate recent methodological advances in this field, and foster interactions among researchers from academia, pharmaceutical and technology industries, clinical research, and public health sectors.

Topics of interest include, but are not limited to:

• Methods to describe, classify and represent the heterogeneity of individual trajectories of ageing from multimodal and longitudinal data sets, with the aim for instance, to understand how genetic, life-style or environmental factors affect ageing;
• Dynamical models of disease progression integrating various clinical or preclinical data across scales and organs, including omics, cellular and medical imaging, physiological, cognitive, behavioral, and clinical assessments in health or disease, in humans or animal models;
• Mechanistic models of disease progression, such as pathogen spreading models in neurodegenerative diseases;
• Development of data-driven tools for precision medicine including personalised prediction of risks, prediction of future adverse events, and recommendations of personalised prevention or therapeutic strategies;
• Development of novel strategies for the identification, screening and stratification of at-risk population, including the use of digital devices or sensor data;
• Development of new clinical trial design to assess the efficacy of disease modifying agents in progressive diseases, including methods for simulation of treatment effects on ageing or disease progression;
• Methods for the analysis of epidemiological or real world data sets with the aim to identify risk factors, or assess long-term efficacy of public health policies.

We encourage contributions from early career researchers from academia and industry.

CompAge 2020 will be the final workshop of the EuroPOND* project, funded within the Horizon 2020 program of the European Union, and the follow-up of a disease progression modelling workshop funded by several Innovative Medicines Initiative (IMI) projects.

CompAge 2020 is committed to providing an atmosphere that encourages the free expression and exchange of ideas. Consistent with this commitment, CompAge 2020 adopts the Code of Conduct of the MICCAI Society. CompAgeg 2020 is endorsed by the MICCAI Society.